Table 3. Analysis of variables associated with overall survival in NSCLC EGFR-mutant patients.
Univariate | Multivariate | |||||
Predictors | HR | 95% CI | P | HR | 95% CI | P |
Age ≥60 years | 1.30 | 0.69–2.46 | 0.413 | 1.23 | 0.62–2.44 | 0.556 |
Male gender | 1.05 | 0.61–1.82 | 0.849 | 1.04 | 0.54–2.02 | 0.907 |
Current/former smoker | 0.98 | 0.53–1.80 | 0.940 | 0.93 | 0.44–1.97 | 0.844 |
Stage 4/recurrence | 0.89 | 0.42–1.90 | 0.768 | 1.11 | 0.49–2.49 | 0.804 |
ECOG PS 3–4 | 1.93 | 1.04–3.57 | 0.036 | 1.64 | 0.84–3.18 | 0.147 |
Subtype of EGFR ‡ | ||||||
exon 19 | 0.63 | 0.36–1.10 | 0.107 | 0.82 | 0.44–1.50 | 0.515 |
exon 18 or 20 | 0.85 | 0.30–2.40 | 0.766 | 0.70 | 0.24–2.06 | 0.516 |
TKI non-response | 2.74 | 1.52–4.94 | 0.001 | 2.74 | 1.43–5.24 | 0.002 |
reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase inhibitor, ECOG PS: eastern cooperation oncology group performance status, HR: hazard ratio, CI: confidence interval